Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...
Clinical Trials Arena on MSN1d
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
MPR1d
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
BofA lowers Arvinas price target to $28, calls selloff ‘overdone’
BofA lowered the firm’s price target on Arvinas (ARVN) to $28 from $54 and keeps a Buy rating on the shares after the Phase 3 VERITAC-2 trial ...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Seeking Alpha1d
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy
The 624-subject global study evaluated patients’ progression-free survival (PFS) as a primary endpoint in the intent-to-treat and estrogen receptor 1-mutant (ESR1m) populations, while their ...